Revenue $674.14M, up 16.5% on a year earlier. Diluted EPS $0.04 against $0.07.
| Q2 FY26 | Q1 FY26 | Q2 FY25 | Year over year | |
|---|---|---|---|---|
| Revenue | $674.14M | $630.58M | $578.66M | +16.5% |
| Operating income | $133.12M | $563.04M | $209.80M | -36.5% |
| Net income | $17.88M | $294.69M | $32.18M | -44.4% |
| Diluted EPS | $0.04 | $0.67 | $0.07 | |
| Operating cash flow | $728.46M | $718.23M | $363.98M | +100.1% |
| Dividend per share | $0.23 | $0.23 | $0.22 |
The week's biggest guidance misses, KPI surprises and one chart.
Stock Atlas, “Royalty Pharma (RPRX) Q2 FY26 earnings: results and KPIs”, stockatlas.com/companies/RPRX/earnings/2026-q2/, data as of 3 November 2026. Links to this page are welcome.
